FDA clears da Vinci 5 for selected cardiac procedures, including mitral valve repair

Intuitive Surgical/da Vinci 5

The FDA cleared da Vinci 5 for mitral valve repair and replacement, internal mammary artery mobilisation for bypass grafting, and closure of cardiac wall defects. A limited number of US hospitals will deploy systems during 2026.

• Mitral valve procedures expand da Vinci 5's initial March 2024 clearance for general, thoracic and urological surgery.
• Internal mammary artery mobilisation supports off-pump coronary artery bypass procedures.
• Cardiac wall defect closure uses robotic precision for minimally invasive access to the heart.
• Hospital deployment through 2026 marks da Vinci 5's entry into cardiothoracic surgery markets.